Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics where Folkert van Bruggen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Re “Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA” — Perspective on potential weight-independent effects
Van Bruggen, F. H., Jan-2026, In: Sleep Medicine. 137, 1 p., 108650.Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review
Open AccessFile1 Downloads (Pure) -
Comment on Chwal et al. On-Target Low-Density Lipoprotein Cholesterol in Adults with Diabetes Not at High Cardiovascular Disease Risk Predicts Greater Mortality, Independent of Early Deaths or Frailty. J. Clin. Med. 2024, 13, 7667
van Bruggen, F. H. & Luijendijk, H. J., Apr-2025, In: Journal of Clinical Medicine. 14, 8, 2 p., 2559.Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review
Open AccessFile2 Citations (Scopus)11 Downloads (Pure) -
Is Targeting LDL-C Levels Below 70 mg/dL Beneficial for Cardiovascular and Overall Health? A Critical Examination of the Evidence
van Bruggen, F. H. & Diamond, D. M., May-2025, In: Journal of Clinical Medicine. 14, 10, 15 p., 3569.Research output: Contribution to journal › Review article › peer-review
Open AccessFile3 Citations (Scopus)59 Downloads (Pure) -
Rethinking Cholesterol-lowering Medication: Exploring Disease Delay, Serious Adverse Events, and Room for Discontinuation
van Bruggen, F., 2025, [Groningen]: University of Groningen. 225 p.Research output: Thesis › Thesis fully internal (DIV)
Open AccessFile464 Downloads (Pure) -
Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisal
van Bruggen, F. H. & Luijendijk, H. J., 2025, In: Frontiers in cardiovascular medicine. 12, 4 p., 1564432.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile5 Downloads (Pure)